Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening.

[1]  C. Berg,et al.  Identification of candidates for longer lung cancer screening intervals following a negative low-dose computed tomography result. , 2019, Journal of the National Cancer Institute.

[2]  C. la Vecchia,et al.  Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  D. Aberle,et al.  MILD trial, strong confirmation of lung cancer screening efficacy , 2019, Nature Reviews Clinical Oncology.

[4]  G. Corrao,et al.  Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  P. Massion,et al.  Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Bram van Ginneken,et al.  Long‐Term Active Surveillance of Screening Detected Subsolid Nodules is a Safe Strategy to Reduce Overtreatment , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  M. Oudkerk,et al.  PL02.05 Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial , 2018, Journal of Thoracic Oncology.

[8]  H. Kauczor,et al.  Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach. , 2018, Lung cancer.

[9]  B. van Ginneken,et al.  Lung cancer risk to personalise annual and biennial follow-up computed tomography screening , 2018, Thorax.

[10]  Harry J de Koning,et al.  Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening , 2017, Thorax.

[11]  H. D. de Koning,et al.  Risk stratification based on screening history: the NELSON lung cancer screening study , 2017, Thorax.

[12]  D. Origgi,et al.  Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis , 2017, British Medical Journal.

[13]  A. Miller,et al.  Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness. , 2016, Lung cancer.

[14]  P. V. van Ooijen,et al.  Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval , 2016, Thorax.

[15]  B. Kramer,et al.  Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. , 2016, The Lancet. Oncology.

[16]  Lisa M. Schwartz,et al.  Patients’ Knowledge, Beliefs, and Distress Associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter Survey , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Asger Dirksen,et al.  Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. , 2016, American journal of respiratory and critical care medicine.

[18]  U. Pastorino,et al.  Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen , 2016, European Radiology.

[19]  M. Scorsetti,et al.  Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. , 2015, American journal of respiratory and critical care medicine.

[20]  Harry J de Koning,et al.  Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. , 2014, The Lancet. Oncology.

[21]  C. la Vecchia,et al.  Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  William Hazelton,et al.  Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force , 2014, Annals of Internal Medicine.

[23]  Ugo Pastorino,et al.  Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial , 2012, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[24]  L. Walter,et al.  Cancer screening in elderly patients: a framework for individualized decision making. , 2001, JAMA.

[25]  H. D. de Koning,et al.  Lung cancer screening: latest developments and unanswered questions. , 2016, The Lancet. Respiratory medicine.

[26]  M. Oudkerk,et al.  Computed tomographic characteristics of interval and post screen carcinomas in lung cancer screening , 2014, European Radiology.

[27]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .